PHI´s new software available for customer delivery

July 9, 2018
Language flag

The newly developed software HoloMonitor® App Suite has now successfully undergone the final field testing at selected HoloMonitor users around the world. Overall, the intuitive user interface, simple work flow, and the few steps to results are much appreciated. The very positive feedback means that HoloMonitor® App Suite 1.0 is now, earlier than planned, available for sales. App Suite complements the existing Hstudio software, to allow basic cell analysis with a higher level of automation, and less manual work than before.

In this first version of App Suite three common analyzes are included: cell proliferation, cell motility, and cell quality control. App Suite will be rapidly expanded with additional applications. HoloMonitor® App Suite 2.0 is scheduled to be released to customers in Q4 2018. More information about App Suite is available here.

Peter Egelberg, CEO and founder of PHI explains: “With App Suite we make HoloMonitor technology available to a broader customer segment. So far, we have through the Hstudio software appealed mostly to technology interested researchers with unique and specific biological questions. While Hstudio offers flexibility and advanced analyses, App Suite offers a range of basic cell biological applications where the results are presented automatically.”

Investor event

App Suite will be shown during the investor event that will be held at 17:00 – 19:00 on Thursday July 12, 2018 at the company’s premises, Scheelevägen 22 in Lund. Please, send a notice of participation to ir@phiab.se no later than July 10. For additional information regarding the ongoing rights issue see www.phiab.se/rights-issue.

Latest News

Peter Egelberg CEO PHI

Founder and board member subscribes for shares in the ongoing rights issue

Peter Egelberg, founder and Board member of Phase Holographic Imaging PHI AB has notified the Company that he, together with closely related parties, follows Altium SA’s lead by subscribing for shares in the Company’s ongoing fully secured rights issue. The subscription amounts to approximately 300 TSEK.
AndersMansson-web

PHI at Aktieportföljen Live, BioStock and Financial Stockholm

The subscription period in PHI AB’s fully secured rights issue, totalling SEK 64.3 million, is ongoing until 20 December 2024. The Company’s CEO, Anders Månsson, has during the last couple of weeks presented the Company and its future plans. For links to the presentations and the podcast, see below.

Notice of Annual General Meeting in Phase Holographic Imaging PHI AB (publ) 8 January 2025

The shareholders of Phase Holographic Imaging PHI AB (publ), (“the Company”), reg.no. 556542-7811, are hereby invited to attend the general meeting on 8 January 2025 at 15.00 at the Company´s office at Skiffervägen 48 in Lund.
See All News